Imagio OA/US
DeviceImagio optoacoustic
NCT Number: NCT05084729
This registry has been designed to obtain real-life, post-market data on the use of the Imagio breast imaging system. This registry is sponsored by Seno Medical Instruments, Inc., the manufacturer of the device.
Looking for future studies?
Notify Me18 year and older
Female
Observational
Rijnstate Hospital, Arnhem, Netherlands
This is a prospective, controlled, multi-center, observational international registry designed to evaluate the Imagio breast imaging system. The registry will be conducted at up to 12 international centers. Investigators will use Imagio US (IUS) and/or Imagio OA/US imaging per standard of care, anddata will be collected accordingly. Additional imaging and biopsy/surgery will be conducted per standard of care to reach a final diagnosis.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Subjects must meet all the following criteria to be included in the registry:
Exclusion criteria
- Aligned with the contraindications on the use of the device, subjects who meet any of the following criteria will be excluded from the registry:
Imagio optoacoustic
Time frame: September 2024
This parameter will be reviewed for the Intention-to-Diagnose (ITD) and Per-Protocol (PP) populations
Time frame: September 2024
This parameter will be reviewed for the Intention-to-Diagnose (ITD) and Per-Protocol (PP) populations
Time frame: September 2024
This parameter will be reviewed for the Intention-to-Diagnose (ITD) and Per-Protocol (PP) populations
Time frame: September 2024
i.e., the correlation of Imagio OA/US feature scoring with histologic grade, ER and PR hormone receptors, HER2 receptor (IHC and/or HER2 FISH), Ki-67 proliferative index, as well as with molecular subtypes of breast cancer.
This parameter will be reviewed for the Intention-to-Diagnose (ITD) and Per-Protocol (PP) populations
Time frame: September 2024
This parameter will be reviewed for the Safety population
Time frame: September 2024
This parameter will be reviewed for the Safety population
Time frame: September 2024
This parameter will be reviewed for the Safety population
Seno Medical Instruments Inc.
Industry
A Multi-Center InternatiONal Registry to Evaluate the Efficacy oF Imaging With Opto-acoustics to Diagnose BrEast CaNCEr
Acronym: CONFIDENCE
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.